We have the patients you need! When a top 10 pharmaceutical company needed to recruit patients with the rare Autosomal Dominant Polycystic Kidney Disease (ADPKD), we used multiple concurrent strategies to find and pre-screen hundreds of patients — and met all the key data privacy regulations and certifications across multiple countries. Learn more in this case study: https://lnkd.in/gMsm-UPb #lifesciences #clinicalresearch #patientrecruitment #raredisease #PKDAwarenessDay
SubjectWell’s Post
More Relevant Posts
-
Marketing & communications leader | Delivering bottom-line impact | Patient & caregiver advocate
Patients need clinical trials. Clinical trials need patients. SubjectWell's Patient Network has 13 million+ patients who have already expressed the desire to participate in clinical trials and try new treatments. #patientrecruitment #patientengagement #clinicaltrials
We have the patients you need! When a top 10 pharmaceutical company needed to recruit patients with the rare Autosomal Dominant Polycystic Kidney Disease (ADPKD), we used multiple concurrent strategies to find and pre-screen hundreds of patients — and met all the key data privacy regulations and certifications across multiple countries. Learn more in this case study: https://lnkd.in/gMsm-UPb #lifesciences #clinicalresearch #patientrecruitment #raredisease #PKDAwarenessDay
-
-
Adverse drug events (ADEs) can include falls, emergency room visits, hospitalizations, morbidities, and even premature death. Our partnership with healthŌme combines our expertise in pharmaceutical sciences with healthŌme's pharmacogenomic testing to reduce the risk of ADEs for policyholders. For more information: https://lnkd.in/eb5vTw9H #MedicationSafety #ADEawareness #Pharmacogenomics
-
-
A report released by the The Pharmaceutical Security Institute (PSI) found that pharmaceutical crime incidents increased by 38%📈 due to COVID-19. The COVID-19 pandemic massively interfered with the effort to reduce 💊#SF medicines and medical products, and the repercussion of the pandemic continues to affect this global issue. Learn more in the Fight the Fakes Alliance report here: https://bit.ly/3LIKh5I #FighttheFakes #fakemeds
-
-
Our latest regulatory strategy webinar, "Obtaining Orphan Drug Designations for Rare Disease Treatments" is now available to view on-demand. This free, one-hour webinar can be accessed at: https://ow.ly/1FOp50Stl6Q. This webinar is the second installment of our Navigating the FDA Roadmap Workshop series. If you missed the first webinar about understanding the IND process, you can watch it on-demand at: https://ow.ly/GKVf50StlgC. #drugdevelopment #lifesciences #webinar #regulatory #pharma #FDA #EMA #orphandiseases #orphandrugs #regulatoryaffairs #clinicaltrials
-
-
🚨 **The Threat of Illegal Online Pharmacies to Public Health** 🌐 Our latest analysis reveals significant risks posed by unauthorized online pharmacies. Understand the implications for patient safety and regulatory challenges. Stay ahead in safeguarding public health. #pharma #DigitalRisk
Illegal online “pharmacies” are on the rise, posing serious risks to patient safety. Pharmaceutical brands and consumers must stay informed and vigilant. In this article from Speciality Pharmacy Continuum, Nisos Intelligence Fellow Vincas Čižiūnas gives insight into these dangers and the alarming tactics used to bypass detection. Check out the full article here: https://lnkd.in/e9M3nikf #ManagedIntel #OSINT #Pharma #DigitalRisk
-
-
🚨 Pulse Newsletter: Essential Updates in PBM & Drug Safety 🚨 Delivered right to your feed—quick, concise, and impactful. 🔍 Clinical Pharmacy Update FDA approves the first needle-free nasal spray for emergency treatment of anaphylaxis. ⚠️ Drug Safety Baxter recalls a lot of Heparin Sodium Injection—your safety, our priority. 💊 Pharmaceutical News FDA greenlights auto-Injector to combat opioid overdoses. 🆕 New Drugs Yorvipath® for hypoparathyroidism Livdelzi® for rare blood disorders like PNH and aHUS. Stay informed and ahead of the curve! 🔗 Read the full newsletter: https://bit.ly/47aJy7g #PharmacyNews #DrugSafety #FDAApprovals #HealthcareUpdates #PBMIndustry #PulseNewsletter
-
-
The first two installments of the Navigating the FDA Regulatory Roadmap Webinar Series are available to view on-demand. Don't miss Paula Garcia Calavia, Ph.D. with "The Investigational New Drug Application (IND) Process," and Darius J. Devlin, Ph.D. with "Obtaining Orphan Drug Designations for Rare Disease Treatments." You can view the Investigational New Drug Application (IND) Webinar here, https://ow.ly/bgYC50SCxvr You can view the Orphan Drug Designation Webinar here, https://ow.ly/I5bs50SCxB8 #drugdevelopment #lifesciences #webinar #regulatory #pharma #FDA #EMA #orphandiseases #orphandrugs #regulatoryaffairs #clinicaltrials
-
-
💬 Niklas Hedberg (Chief Pharmacist at 🇸🇪 The Dental and Pharmaceutical Benefits Agency, TLV) reflected on the significance of the RWE4Decisions Stakeholder Actions to Generate better Real World Evidence for HTA and Payers at our public webinar. 🎥 Watch the webinar recording & find out more about the Actions for Stakeholders: https://lnkd.in/eUs5sFWb 🔗 #RealWorldEvidence #RWE #RealWorldData #RWD #HealthTechnologyAssessment #HTA #Payers #HealthData #EHDS #HTAR #StakeholderActions
-
-
🚀 Latest Pharma News You Can't-Miss! 🚀 ▶ Merck completes the acquisition of EyeBio, advancing Restoret™ for retinal diseases. ▶ The Affordable Prescriptions for Patients Act advances in the Senate to foster generic drug competition. ▶ Alembic Pharmaceuticals Limited receives USFDA tentative approval for Selexipag Injection to treat PAH. ▶ AbbVie seeks FDA and EMA approval for Upadacitinib to treat Giant Cell Arteritis. ▶ Federal court rejects Boehringer Ingelheim's challenge to Medicare drug price negotiation. 📲 Read the complete story at www.pharmanow.live Stay informed with the latest breakthroughs and regulatory updates! 📈✨ #PharmaNow #Merck #EyeBio #AlembicPharma #AbbVie #BoehringerIngelheim #PharmaNews #IndustryUpdate
-
Helping CEOs, CFOs and HR Professionals modernize and maximize their company's employee benefits program.
For those considering Ozempic/Mounjaro, it's crucial to be aware of potential side effects. Patients are suing GLP1 drug makers due to serious allegations. A lawsuit highlights claims of gastroparesis, a condition that profoundly impacts digestion. The lawsuit alleges that the manufacturers failed to adequately warn patients about these risks. Check out the full story here: #Pharmaceuticals #DrugSafety #GLP1 #PatientCare #Healthcare #MedicalNews
